SKINVISIBLE Reports Worsening Financials, $1.8K Cash, and Persistent Going Concern Warning
SKVI has more than doubled off its 52-week low of $0.055 on light trading volume (0.1× avg).
Summary
SKINVISIBLE, INC. reported a critical financial state in Q1 2026 with only $1,798 in cash, a worsening working capital deficit, and a reiterated 'going concern' warning, compounded by a lack of new financing and persistent internal control weaknesses.
Key Events · Earnings and Guidance · SKVI
-
Going Concern Warning Reaffirmed
Management explicitly reiterated its 'going concern' warning, indicating substantial doubt about the company's ability to continue operations within the next year due to cumulative losses and capital requirements.
-
Critical Cash Position
The company's cash balance plummeted to a mere $1,798 as of March 31, 2026, down from $2,620 at the end of 2025, signaling an acute liquidity crisis.
-
Worsening Working Capital Deficit
The working capital deficit expanded to $5,252,591 as of March 31, 2026, worsening from $4,990,414 at December 31, 2025, reflecting increasing short-term liabilities relative to assets.
-
No New Financing in Q1 2026
SKINVISIBLE, INC. reported $0 in cash provided from financing activities for the three months ended March 31, 2026, indicating a failure to secure new capital during a period of critical need.
Analysis · SKVI · Life Sciences
SKINVISIBLE, INC. continues to face critical financial instability, as evidenced by its Q1 2026 results. The company's cash balance has dwindled to an alarming $1,798, and its working capital deficit has worsened to over $5.2 million. The explicit 'going concern' warning, previously noted in the annual report, is reiterated, indicating management's substantial doubt about the company's ability to continue operations. Furthermore, the company reported no cash provided from financing activities in Q1 2026, highlighting a failure to secure new capital amidst its dire liquidity crisis. Material weaknesses in internal controls also persist, raising significant governance concerns. The potential for massive dilution from over 82 million shares issuable from convertible notes, compared to only 5.4 million shares outstanding, represents a substantial future overhang for shareholders.
At the time of this filing, SKVI was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $1M. The 52-week trading range was $0.06 to $0.90. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.